close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.640 -0.030 (-1.80%)
Streaming Delayed Price Updated: 12:25 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about OS Therapies Incorporated Common Stock

News headline image
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate ↗
OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results. 
Via Benzinga
News headline image
Os Therapies Posts Wider Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Earnings Outlook For OS Therapies ↗
 
Via Benzinga
News headline image
OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024 ↗
OS Therapies just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Which stocks are gapping on Monday? ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer ↗
OS Therapies advances OST-HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma. 
Via Benzinga
News headline image
Friday's session: gap up and gap down stocks ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Top movers in Friday's pre-market session ↗
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why ↗
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves. 
Via Stocktwits
News headline image
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? ↗
OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector 
Via News Direct
News headline image
Transforming Oncology: Stocks to Watch in the Oncology Sector
Transforming Oncology: Stocks to Watch in the Oncology Sector 
Via News Direct
News headline image
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
OS Therapies Falls Following Downsized IPO ↗
Shares of OS Therapies fell on Thursday following a downsized initial public offering by the oncology drug developer in a slow week for the IPO market. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Dow Dips Over 400 Points; Apple Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today